BioCina Pty Ltd., a globally renowned biologics contract development and manufacturing organization (CDMO), has recently announced an expanded partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company focused on developing Gamma-PN™, a proprietary engineered whole-cell vaccine targeting Streptococcus pneumoniae, a bacterium responsible for life-threatening infections like pneumonia, bacteremia, and meningitis, leading to up to 2 million annual deaths worldwide. GPN's vaccine technology utilizes a proprietary engineered strain of Streptococcus pneumoniae that lacks capsular polysaccharides and expresses common surface proteins shared across all serotypes. This technology induces a broad-spectrum immune response, involving T- and B-cells, which outperforms currently approved vaccines.

BioCina will be responsible for the large-scale cGMP batch manufacturing for this program. The BioCina facility in Adelaide, Australia, has a strong history of developing and manufacturing recombinant proteins in microbial systems, including E. coli.

BioCina, expressed his pride, saying, "We are honored that GPN Vaccines has chosen us to expand the production of Gamma-PN™, a vaccine with the potential to protect countless lives against a wide range of serotypes not covered by existing vaccines."

GPN Vaccines, added, "We are excited to move forward with the next stage of cGMP manufacturing for our innovative whole-cell pneumococcal vaccine, Gamma-PN™, with BioCina as our preferred CDMO. They have successfully optimized the production of Phase 1 material, and we look forward to collaborating with them to develop a scaled-up manufacturing process for Phase 2 material suitable for global clinical evaluation."

 

Source: prnewswire.com

Report Abuse